Company Overview - KDventures AB, a Nordic investment company specialized in life sciences, has a 33% ownership stake in SVF Vaccines, which is focused on developing DNA vaccines and immunotherapies based on proprietary technology from Karolinska Institutet [5][6]. Leadership Appointment - SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition of its lead vaccine candidate SVF-001 into phase 1 clinical development [1][2]. - Nassaji brings nearly two decades of experience in big pharma, biotech, and healthcare innovation, with a strong background in clinical development, capital strategy, and business development [3]. Strategic Focus - Raheleh Nassaji emphasized the importance of disciplined clinical execution, building a strong financing and partnering strategy, and positioning SVF Vaccines for long-term value creation as the company generates early clinical data [4]. - The leadership change comes at a critical stage for SVF Vaccines as it prepares to enter first-in-human clinical trials with SVF-001 [2][5].